What is Cobenfy and how does it differ from older schizophrenia drugs?

Cobenfy is a new type of antipsychotic drug for schizophrenia that targets muscarinic receptors, aiming to reduce side effects like weight gain and movement disorders, unlike older drugs that target dopamine receptors.

Why are insurance companies creating barriers for Cobenfy access?

Insurers are reportedly impeding access to Cobenfy by requiring patients to first try and fail other brand-name drugs, despite the risks associated with ineffective treatment for schizophrenia.

What are the sales expectations for Cobenfy and why has it struggled?

Bristol Myers Squibb faces pressure as Cobenfy sales lag expectations, with analysts having reduced initial forecasts due to slow adoption by psychiatrists and insurance obstacles.

Home / Health / New Schizophrenia Drug Faces Insurance Hurdles

New Schizophrenia Drug Faces Insurance Hurdles

28 Apr

•

Summary

Cobenfy offers new hope for schizophrenia patients, targeting different receptors.
Insurers impede access, requiring patients to try less effective drugs first.
Bristol Myers Squibb faces pressure as Cobenfy sales lag expectations.

New Schizophrenia Drug Faces Insurance Hurdles

Cobenfy, a new class of drug for schizophrenia, offers a potential breakthrough for millions affected by the condition. Unlike older treatments targeting dopamine, Cobenfy focuses on muscarinic receptors, aiming to reduce debilitating side effects such as weight gain and movement disorders. This novel approach promises better patient adherence and an improved quality of life.

Despite its potential, Cobenfy's market entry has faced significant challenges. Insurers are placing barriers to coverage, often requiring patients to first exhaust other brand-name medications, a process that can be risky for those with schizophrenia. This has led to slower-than-anticipated adoption by psychiatrists, who are accustomed to prescribing older, generic treatments.